Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma

Carcinogenesis

Volumn 35, Issue 2, 2014, Pages 373-382

  Shao, Rong ^a   Francescone, Ralph ^a   Ngernyuang, Nipaporn ^b   Bentley, Brooke ^c   Taylor, Sherry L ^d   Moral, Luis ^c   Yan, Wei ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b KHON KAEN UNIVERSITY   (Thailand)

^c TUFTS UNIVERSITY   (United States)

^d BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE CELL ADHESION MOLECULE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; YKL 40 ANTIBODY;

ADJUVANT THERAPY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN TUMOR; CANCER RADIOTHERAPY; CELL ACTIVITY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IRRADIATION; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; SURVIVAL; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADIPOKINES; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LECTINS; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION, IONIZING;

EID: 84893364479     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt380     Document Type: Article

References (44)

1. Wen,P.Y. et al. (2008) Malignant gliomas in adults. N. Engl. J. Med., 359, 492-507.
2. Norden,A.D. et al. (2009) Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol., 5, 610-620.
3. Singh,S.K. et al. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401.
4. Zheng,H. et al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature, 455, 1129-1133.
5. Beier,D. et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res., 67, 4010-4015.
6. Zheng,H. et al. (2010) PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell, 17, 497-509.
7. Kendall,S.E. et al. (2008) Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells, 26, 1575-1586.
8. Méndez,O. et al. (2010) Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol. Cancer, 9, 133.
9. Scully,S. et al. (2012) Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J. Neurosci., 32, 12950-12960.
10. El Hallani,S. et al. (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain, 133(Pt 4), 973-982.
11. Ricci-Vitiani,L. et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 468, 824-828.
12. Wang,R. et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 468, 829-833.
13. Fusetti,F. et al. (2003) Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J. Biol. Chem., 278, 37753-37760.
14. Hu,B. et al. (1996) Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J. Biol. Chem., 271, 19415-19420.
15. Nyirkos,P. et al. (1990) Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem. J., 269, 265-268.
16. Shackelton,L.M. et al. (1995) Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol. Chem., 270, 13076-13083.
17. Rehli,M. et al. (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics, 43, 221-225.
18. Kzhyshkowska,J. et al. (2007) Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark. Insights, 2, 128-146.
19. Malinda,K.M. et al. (1999) Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell Res., 250, 168-173.
20. Scully,S. et al. (2011) Inhibitory activity of YKL-40 in mammary epithelial cell differentiation and polarization induced by lactogenic hormones: a role in mammary tissue involution. PLoS One, 6, e25819.
21. Nigro,J.M. et al. (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res., 65, 1678-1686.
22. Tanwar,M.K. et al. (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res., 62, 4364-4368.
23. Pelloski,C.E. et al. (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res., 11, 3326-3334.
24. Nutt,C.L. et al. (2005) YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin. Cancer Res., 11, 2258-2264.
25. Hormigo,A. et al. (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res., 12, 5698-5704.
26. Ku,B.M. et al. (2011) CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int. J. Cancer, 128, 1316-1326.
27. Saidi,A. et al. (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int. J. Cancer, 122, 2187-2198.
28. Shao,R. (2013) YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front. Physiol., 4, 122.
29. Shao,R. et al. (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene, 28, 4456-4468.
30. Francescone,R.A. et al. (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J. Biol. Chem., 286, 15332-15343.
31. Junker,N. et al. (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci., 96, 183-190.
32. Carmeliet,P. et al. (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307.
33. Hellström,M. et al. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol., 153, 543-553.
34. Francescone,R. et al. (2013) Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis. Oncogene, in press.
35. Faibish,M. et al. (2011) A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol. Cancer Ther., 10, 742-751.
36. Stupp,R. et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
37. Hochberg,F.H. et al. (1980) Assumptions in the radiotherapy of glioblastoma. Neurology, 30, 907-911.
38. Leung,S.Y. et al. (1997) Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol., 93, 518-527.
39. Samaras,V. et al. (2007) Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumors. Mol. Cell. Biochem., 304, 343-351.
40. Cheng,L. et al. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell, 153, 139-152.
41. Lee,J. et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 9, 391-403.
42. Verhoeff,J.J. et al. (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer, 9, 444.
43. Rinne,M.L. et al. (2013) Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin. Emerg. Drugs, 18, 137-153.
44. Wick,W. et al. (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J. Clin. Oncol., 28, e188-9; author reply e190.